A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib
A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib

Olivia M Lucero¹ MD, Sarah Fitzmaurice¹ MD, Curtis Thompson¹,²,³ MD, and Justin Leitenberger¹ MD

Affiliations:¹Departments of Dermatology, ²Pathology and ³Biomedical Engineering, Oregon Health & Sciences University, Portland, Oregon

Corresponding Author: Justin Leitenberger MD, OHSU Center for Health & Healing, 3303 SW Bond Avenue, Suite 16D, Portland, OR 97239, Tel: 503-418-3376, Email: leitenbe@ohsu.edu

Abstract
Vismodegib is a small molecule inhibitor of the Hedgehog signaling pathway that has shown efficacy in the control of locally advanced or metastatic basal cell carcinoma, although proof of its effectiveness in the elimination of aggressive tumors is lacking. We report a case and provide complete histological evidence of a 69-year-old gentleman who presented with a recurrent, infiltrative, and sclerosing (morpheiform) basal cell carcinoma on his left upper lip that was entirely eradicated with a three-month course of vismodegib 150 mg daily. Complete histologic clearance of a tumor in a recurrent, infiltrative, and sclerosing basal cell carcinoma with vismodegib is uncommon.

Keywords: basal cell carcinoma, vismodegib, hedgehog pathway

Introduction
Genetic alterations in the sonic hedgehog (SHH) pathway leading to aberrant activation and uncontrolled basal cell proliferation underlie the majority of basal cell carcinomas (BCC), [1]. Most commonly, this involves inactivating mutations in the Patched tumor suppressor gene, which encodes PTCH, a transmembrane protein that inhibits the downstream effects of the protein, Smoothened (SMO). Binding of SHH to PTCH leads to dissociation and subsequent activation of SMO, allowing for pathway activation and transcription of gene products that promote cellular proliferation. Although the majority of BCCs are effectively treated with surgery, topical chemotherapy, or radiotherapy, a minority of tumors are locally advanced and necessitate other treatment options. Vismodegib, a small molecule inhibitor of SMO, has shown efficacy in treating both primary and recurrent BCC, though its efficacy in complete clearance of recurrent or histologically aggressive tumors has been lacking [1, 2]. This is especially important given adaption of compensatory tumor survival pathways or alteration of the drug binding site that underlies tumor resistance and recurrence [3]. Highlighting the use of vismodegib as an efficacious treatment in these circumstances can provide the patient and provider with a greater number of options. In this case, we present histopathological evidence of complete tumor clearance in an aggressive, recurrent BCC following treatment with vismodegib.

Case Synopsis
A 69-year-old man with a history of hepatitis C and hypertension presented with an extensive, recurrent BCC on his left upper lip. He first noticed the BCC three years prior to presentation in the area of a traumatic scar. The patient sought care one year later and the lesion was excised. He then experienced
reappearance of nodules at the same site one year following surgery. At that time, he was noted to have a 2.8 x 1.8 cm firm, hairless, violaceous, pearly plaque abutting the left nostril sill, blunting the left philtral column, and depressing the superior vermilion lip. A repeat biopsy showed an infiltrative and sclerosing-type of BCC (Figure 1). Given the size, location, and history of recurrence, he was started on vismodegib 150mg once per day at an outside clinic. He was noted to have an approximate 50% visual reduction in tumor mass after one month on the drug. After 3 months of treatment, there was inability to clinically differentiate scar tissue from residual tumor (Figure 2A). Given the size reduction, he was felt to be a surgical candidate and underwent Mohs micrographic surgery, stage 1, resulting in a 3.0cm x 2.7cm defect (Figure 2B). A central debulk was performed and frozen sections of the bread-loafed area demonstrated scar tissue and complete absence of residual tumor (Figure 3). The mapped complete circumferential peripheral and deep margins showed no involvement of residual tumor.

**Case Discussion**

This case demonstrates complete histological resolution after 3 months of vismodegib in a
recurrent, infiltrative and sclerosing BCC. Although vismodegib has been shown to be an effective means of BCC control, proof of its efficacy in eradicating tumors has been limited, in part by study design. A phase II study (ERIVANCE) demonstrated complete response in 13 of 63 patients with primary BCC [1]. A subsequent open label trial of inoperable BCC showed a complete response in 6 of 56 patients with locally advanced disease [2]. A recent report illustrated clinical clearance of a recurrent, infiltrative BCC following 3 months of vismodegib with biopsy 8 months after treatment revealing no residual tumor [4]. Complete response in these cases was based on biopsies, a technique flawed by potential sampling error, or clinical disappearance of visible target lesions. Whereas studies examining vismodegib as an adjuvant to Mohs have presented an opportunity for histological analysis of tumor response, no trials have shown eradication of recurrent tumors. One clinical trial by Ally et al. utilized first piece serial sectioning followed by standing cone confirmation to demonstrate complete response in 6 of 13 primary tumors; all recurrent tumors had residual BCC [5]. Another clinical trial conducted by Sofen et al. performed serial sectioning of paraffin embedded tumors with 16% of tumors demonstrating complete histological clearance [6]. These patients, however, all had primary tumors. A case series by Alcalay et al. reported incomplete tumor resolution of three large, aggressive BCCs treated with vismodegib followed by Moh’s surgery; residual tumor islands were visible in all sections [7].

Previous studies have shown that BCCs that recur after surgery often require multiple Mohs stages and are less likely to respond to vismodegib, highlighting the aggressive phenotype of these tumors [8, 9]. Our case demonstrates the potential use of vismodegib in aggressive, recurrent tumors with histological evidence of full tumor clearance, an important finding that highlights the heterogeneity in tumor survival and susceptibility to targeted therapy.

Conclusion

We demonstrate histopathologic evidence of the eradication of a recurrent morphoform BCC following a 3-month course of vismodegib, illustrating the potential of this targeted therapy to definitively treat an aggressive BCC.

References


